查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301160

医疗保健合同开发和製造机构的市场规模、份额和趋势分析报告：2023-2030 年按服务（合同开发、合同製造）、地区和细分市场划分的趋势

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 175 Pages | 商品交期: 2-10个工作天内

价格

医疗保健外包开发和製造机构市场的增长和趋势

Grand View Research, Inc. 的新报告预测，到 2030 年，全球医疗保健合同开发和製造组织市场将达到 4710 亿美元。

从 2023 年到 2030 年，市场预计将以 9.5% 的复合年增长率扩张。 由于研发支出的增加和外包趋势的增加，预计该市场将出现利润丰厚的增长。

医疗保健合同开发和製造组织 (CDMO) 在合同基础上向各个製药行业提供外包服务。 製药公司外包的增加、製药行业的扩张以及 CDMO 在降低运营和资本成本方面的帮助是预计在预测期内推动市场增长的一些关键因素。

此外，製药和医疗器械公司满足严格时间表的压力越来越大，这增加了将开发和製造活动外包给 CDMO 的需求。 此外，由于新兴国家对医疗器械的需求不断增加，各公司正在将重点转向医疗器械合同开发和製造的研发活动。 在过去的十年中，多家製药公司转向 CMO、CRO 和 CDMO 来帮助他们预先制定、开发和製造其新颖的创新产品。 外包是一个高增长的市场，大部分支出都集中在早期开发上。

约75%的新药管线来自中小型生物製药公司。 这些公司利润丰厚，对于寻求削减成本的医疗保健提供商来说是有吸引力的目标。 因此，这些公司将服务外包给拥有专业知识和必要设备的第三方，而不是投资建设自己的基础设施是有意义的。 一些製药公司寻求外包服务来优化其分子开发。 例如，美国生物技术公司 Remedium Bio 于 2023 年 3 月宣布，将与比利时 CDMO Exothera 合作，扩大 Remedium 的领先基因治疗候选药物——骨关节炎药物 AAV2-FGF18 的生产。

然而，物流成本上升、医疗机构面临的序列化问题以及知识产权 (IP) 侵权威胁预计将在预测期内抑制医疗保健合同开发和製造组织的市场增长。

医疗保健合同开发和製造组织市场报告亮点

  • 由于製药公司和医疗器械公司外包製造服务的增加，合同製造行业在 2022 年占据市场主导地位，占市场收入份额的 73.5%。
  • 在小分子合同开发子细分市场中，由于新疗法的不断增加，临床前/细分市场预计在预测期内将以 10.4% 的最高复合年增长率增长。
  • 北美在医疗保健合同开发和製造组织市场占据主导地位，2022 年销售份额最大，达到 40.9%。 该地区的高份额主要是由于该地区有大量活跃的 CRO 和 CMO，尤其是在美国。
  • 预计亚太地区在预测期内将以 10.4% 的最快复合年增长率增长。 由于亚洲 CRO 和 CMO 提供的低成本合同开发和製造服务，预计该地区将出现良好的复合年增长率。

内容

第一章调查方法及范围

  • 市场细分和范围
    • 段定义
    • 服务
  • 区域范围
  • 估计/预测时间表
  • 目的
  • 调查方法
  • 信息获取
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
  • 信息或数据分析
    • 数据分析模型
  • 市场形成和验证
  • 型号详细信息
    • 产品流分析
    • 母公司市场分析
  • 辅助信息列表
  • 缩写列表

第 2 章执行摘要

  • 市场前景
  • 分部展望
  • 竞争考虑因素

第 3 章医疗保健 CDMO 市场变量、趋势和范围

  • 市场体系展望
    • 母公司市场前景
    • 相关/补充市场前景
  • 按服务分类的产品渠道分析
  • 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
  • 医疗保健 CDMO 市场分析工具
    • 行业分析 - 搬运工
    • PESTEL 分析
    • COVID-19 的影响分析
    • 主要交易和战略联盟分析

第 4 章医疗 CDMO 市场：服务评估和趋势分析

  • 医疗保健 CDMO 市场（按服务）：细分仪表板
  • 医疗保健 CDMO 市场（按服务）：波动分析
    • 委託开发
    • 合同製造

第五章医疗 CDMO 市场：区域估算和趋势分析

  • 2022 年和 2030 年区域市场份额分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 北美
    • 2018-2030 年市场预估和预测（收入，百万美元）
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
    • 荷兰
    • 比利时
  • 亚太地区
    • 日本
    • 印度
    • 中国
    • 韩国
    • 澳大利亚
    • 泰国
    • 马来西亚
    • 新西兰
    • 新加坡
    • 菲律宾
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 智利
  • MEA
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特
    • 以色列

第 6 章竞争格局

  • 市场进入者分类
    • 创新者
    • 市场领导者
    • 新兴玩家
    • 2022 年公司市场份额分析
  • 公司简介
    • Catalent Inc.
    • Lonza
    • Recipharm AB
    • Siegfried Holding AG
    • Thermo Fisher Scientific, Inc
    • Labcorp Drug Development
    • Jabil Inc
    • Syngene International Limited
    • IQVIA Inc.
    • Almac Group
    • Ajinomoto Bio-Pharma
    • Adare Pharma Solutions
    • Alcami Corporation
    • Vetter Pharma International

第 7 章 KoL 解释/建议

Product Code: GVR-4-68038-438-3

Healthcare Contract Development And Manufacturing Organization Market Growth & Trends

The global healthcare contract development and manufacturing organization market size is expected to reach USD 471.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.5% from 2023 to 2030. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends.

Healthcare Contract Development and Manufacturing Organization (CDMO) provide outsourcing services to various pharmaceutical industries on a contract basis. An increase in outsourcing by pharmaceutical companies, expansions in the pharmaceutical industry, and the support of CDMOs in reducing operational and capital expenses are some of the major factors anticipated to propel the market growth in the forecast period.

In addition, growing pressure on pharmaceutical and medical device companies to follow stringent timelines has increased the demand for outsourcing development and manufacturing activities to CDMOs. Further, due to the increasing demand for medical devices in emerging countries, various companies are shifting their focus on research and development activities for medical device contract development and manufacturing. Over the past 10 years, several pharmaceutical companies have turned to CMOs, CROs, and CDMOs to assist in preformulation and development & manufacturing of their novel innovations. Outsourcing is a high growth market and most spending is focused on early development.

Around 75% of new drug pipelines come from small and midsized biopharmaceutical companies. These companies have high profit margins, which make them easy targets for healthcare providers who are trying to reduce cost. Thus, instead of investing in establishing their own infrastructure, it is profitable for these companies to outsource services to third-party organizations who have expertise and the required equipment. Several pharmaceutical companies are seeking outsourced services for optimizing the development of their molecule. For instance, in March 2023, Remedium Bio, a U.S.-based biotechnology company, entered in a collaboration agreement with Exothera, a Belgium-based CDMO, to scale up the production of Remedium's lead gene therapy drug candidate, AAV2-FGF18 in the treatment of osteoarthritis.

However, increasing logistic costs, serialization issues faced by healthcare organizations, and the threat of infringement of Intellectual Property (IP) rights are anticipated to restrain the market growth for healthcare contract development & manufacturing organization over the forecast period.

Healthcare Contract Development And Manufacturing Organization Market Report Highlights

  • The contract manufacturing segment dominated the market with a revenue share of 73.5% in 2022 due to increase in the outsourcing of manufacturing services by pharmaceutical and medical device companies
  • By small molecule contract development sub-segment, the preclinical/segment is expected to register the highest CAGR of 10.4% in the forecast period due to the rising pipeline of novel therapeutics
  • North America dominated the healthcare contract development and manufacturing organization market with the largest revenue share of 40.9% in 2022. High shares of the region are majorly due to the presence of a large number of actively functioning CROs and CMOs in the region, especially across the U.S.
  • The Asia Pacific is projected to witness the fastest CAGR of 10.4% during the forecast period. The region is anticipated to witness a lucrative CAGR owing to the low-cost contract development and manufacturing services offered by Asian CROs and CMOs

Table of Contents

Chapter 1. Research Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Services
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Healthcare CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Product Pipeline Analysis, by Service
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing Outsourcing Services By Pharmaceutical Companies
      • 3.3.1.2. Rising Investment In R&D
      • 3.3.1.3. Growing Pharmaceutical Industry
      • 3.3.1.4. Increasing Demand For One-Stop-Shop CDMOs
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Compliance Issues While Outsourcing
      • 3.3.2.2. Changing Scenarios In Developing Countries
      • 3.3.2.3. Regulatory And Legal Compliance
  • 3.4. Healthcare CDMO Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier Power
      • 3.4.1.2. Buyer Power
      • 3.4.1.3. Substitution Threat
      • 3.4.1.4. Threat Of New Entrant
      • 3.4.1.5. Competitive Rivalry
    • 3.4.2. PESTEL Analysis
    • 3.4.3. COVID-19 Impact Analysis
    • 3.4.4. Major Deals & Strategic Alliances Analysis
      • 3.4.4.1. Mergers & Acquisitions
      • 3.4.4.2. Geographic Expansions
      • 3.4.4.3. Partnerships
      • 3.4.4.4. Launch
      • 3.4.4.5. Collaborations

Chapter 4. Healthcare CDMO Market: Services Estimates & Trend Analysis

  • 4.1. Healthcare CDMO Market, By Services: Segment Dashboard
  • 4.2. Healthcare CDMO Market, By Services: Movement Analysis
  • 4.3. Healthcare CDMO Market Estimates & Forecasts, By Services, 2018 - 2030
    • 4.3.1. Contract Development
      • 4.3.1.1. Contract Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Small Molecule
      • 4.3.1.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2. Preclinical
      • 4.3.1.2.2.1. Preclinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.2. Bioanalysis and DMPK studies
      • 4.3.1.2.2.2.1. Bioanalysis and DMPK studies Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.3. Toxicology Testing
      • 4.3.1.2.2.3.1. Toxicology Testing Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.4. Other Preclinical Services
      • 4.3.1.2.2.4.1. Other Preclinical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3. Clinical
      • 4.3.1.2.3.1. Clinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.2. Phase I
      • 4.3.1.2.3.2.1. Phase I Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.3. Phase II
      • 4.3.1.2.3.3.1. Phase II Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.4. Phase III
      • 4.3.1.2.3.4.1. Phase III Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.5. Phase IV
      • 4.3.1.2.3.5.1. Phase IV Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4. Laboratory Services
      • 4.3.1.2.4.1. Laboratory Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4.2. Bioanalytical Services
      • 4.3.1.2.4.2.1. Bioanalytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4.3. Analytical Services
      • 4.3.1.2.4.3.1. Analytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Large Molecule
      • 4.3.1.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.2. Cell line development
      • 4.3.1.3.2.1. Cell line development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3. Process Development
      • 4.3.1.3.3.1. Process Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2. Upstream
      • 4.3.1.3.3.2.1. Upstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.2. Microbial
      • 4.3.1.3.3.2.2.1. Microbial Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.3. Mammalian
      • 4.3.1.3.3.2.3.1. Mammalian Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.4. Others
      • 4.3.1.3.3.2.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3. Downstream
      • 4.3.1.3.3.3.1. Downstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.2. MABs
      • 4.3.1.3.3.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.3. Recombinant Proteins
      • 4.3.1.3.3.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.4. Others
      • 4.3.1.3.3.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.2. Contract Manufacturing
      • 4.3.2.1. Contract Manufacturing Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. Small Molecule
      • 4.3.2.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Large Molecule
      • 4.3.2.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.2. MABs
      • 4.3.2.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.3. Recombinant Proteins
      • 4.3.2.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.4. Others
      • 4.3.2.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.4. High Potency API
      • 4.3.2.4.1. High Potency API Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5. Finished Dose Formulations
      • 4.3.2.5.1. Finished Dose Formulations Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.2. Solid Dose Formulation
      • 4.3.2.5.2.1. Solid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.3. Liquid Dose Formulation
      • 4.3.2.5.3.1. Liquid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.4. Injectable Dose Formulation
      • 4.3.2.5.4.1. Injectable Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6. Medical Device
      • 4.3.2.6.1. Medical Device Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.2. Class I
      • 4.3.2.6.2.1. Class I Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.3. Class II
      • 4.3.2.6.3.1. Class II Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.4. Class III
      • 4.3.2.6.4.1. Class III Healthcare CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Healthcare CDMO Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2022 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. North America
    • 5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Competitive Scenario
      • 5.4.2.3. Regulatory Framework
      • 5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Competitive Scenario
      • 5.4.3.3. Regulatory Framework
      • 5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key Country Dynamics
      • 5.5.1.2. Competitive Scenario
      • 5.5.1.3. Regulatory Framework
      • 5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 5.5.2. Germany
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Competitive Scenario
      • 5.5.2.3. Regulatory Framework
      • 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 5.5.3. France
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Competitive Scenario
      • 5.5.3.3. Regulatory Framework
      • 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 5.5.4. Italy
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Competitive Scenario
      • 5.5.4.3. Regulatory Framework
      • 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 5.5.5. Spain
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Competitive Scenario
      • 5.5.5.3. Regulatory Framework
      • 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 5.5.6. Denmark
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Competitive Scenario
      • 5.5.6.3. Regulatory Framework
      • 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 5.5.7. Sweden
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Competitive Scenario
      • 5.5.7.3. Regulatory Framework
      • 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 5.5.8. Norway
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Competitive Scenario
      • 5.5.8.3. Regulatory Framework
      • 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
    • 5.5.9. Netherlands
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Competitive Scenario
      • 5.5.9.3. Regulatory Framework
      • 5.5.9.4. Netherlands Market Estimates and Forecasts, 2018 - 2030
    • 5.5.10. Belgium
      • 5.5.10.1. Key Country Dynamics
      • 5.5.10.2. Competitive Scenario
      • 5.5.10.3. Regulatory Framework
      • 5.5.10.4. Belgium Market Estimates and Forecasts, 2018 - 2030
  • 5.6. Asia Pacific
    • 5.6.1. Japan
      • 5.6.1.1. Key Country Dynamics
      • 5.6.1.2. Competitive Scenario
      • 5.6.1.3. Regulatory Framework
      • 5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 5.6.2. India
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory Framework
      • 5.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory Framework
      • 5.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 5.6.4. South Korea
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Competitive Scenario
      • 5.6.4.3. Regulatory Framework
      • 5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Competitive Scenario
      • 5.6.5.3. Regulatory Framework
      • 5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.6. Thailand
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Competitive Scenario
      • 5.6.6.3. Regulatory Framework
      • 5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
    • 5.6.7. Malaysia
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Competitive Scenario
      • 5.6.7.3. Regulatory Framework
      • 5.6.7.4. Malaysia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.8. New Zealand
      • 5.6.8.1. Key Country Dynamics
      • 5.6.8.2. Competitive Scenario
      • 5.6.8.3. Regulatory Framework
      • 5.6.8.4. New Zealand Market Estimates and Forecasts, 2018 - 2030
    • 5.6.9. Singapore
      • 5.6.9.1. Key Country Dynamics
      • 5.6.9.2. Competitive Scenario
      • 5.6.9.3. Regulatory Framework
      • 5.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030
    • 5.6.10. Philippines
      • 5.6.10.1. Key Country Dynamics
      • 5.6.10.2. Competitive Scenario
      • 5.6.10.3. Regulatory Framework
      • 5.6.10.4. Philippines Market Estimates and Forecasts, 2018 - 2030
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key Country Dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory Framework
      • 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 5.7.2. Mexico
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory Framework
      • 5.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Competitive Scenario
      • 5.7.3.3. Regulatory Framework
      • 5.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
    • 5.7.4. Colombia
      • 5.7.4.1. Key Country Dynamics
      • 5.7.4.2. Competitive Scenario
      • 5.7.4.3. Regulatory Framework
      • 5.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
    • 5.7.5. Chile
      • 5.7.5.1. Key Country Dynamics
      • 5.7.5.2. Competitive Scenario
      • 5.7.5.3. Regulatory Framework
      • 5.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key Country Dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory Framework
      • 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory Framework
      • 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 5.8.3. UAE
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory Framework
      • 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 5.8.4. Kuwait
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Competitive Scenario
      • 5.8.4.3. Regulatory Framework
      • 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
    • 5.8.5. Israel
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Competitive Scenario
      • 5.8.5.3. Regulatory Framework
      • 5.8.5.4. Israel Market Estimates and Forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Innovators
    • 6.1.2. Market Leaders
    • 6.1.3. Emerging Players
    • 6.1.4. Company Market Share Analysis, 2022
  • 6.2. Company Profiles
    • 6.2.1. Catalent Inc.
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Lonza
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Service Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Recipharm AB
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Service Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Siegfried Holding AG
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Service Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Thermo Fisher Scientific, Inc
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Service Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Labcorp Drug Development
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Service Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Jabil Inc
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Service Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. Syngene International Limited
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Service Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. IQVIA Inc.
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Service Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. Almac Group
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Service Benchmarking
      • 6.2.10.4. Strategic Initiatives
    • 6.2.11. Ajinomoto Bio-Pharma
      • 6.2.11.1. Company Overview
      • 6.2.11.2. Financial Performance
      • 6.2.11.3. Service Benchmarking
      • 6.2.11.4. Strategic Initiatives
    • 6.2.12. Adare Pharma Solutions
      • 6.2.12.1. Company Overview
      • 6.2.12.2. Financial Performance
      • 6.2.12.3. Service Benchmarking
      • 6.2.12.4. Strategic Initiatives
    • 6.2.13. Alcami Corporation
      • 6.2.13.1. Company Overview
      • 6.2.13.2. Financial Performance
      • 6.2.13.3. Service Benchmarking
      • 6.2.13.4. Strategic Initiatives
    • 6.2.14. Vetter Pharma International
      • 6.2.14.1. Company Overview
      • 6.2.14.2. Financial Performance
      • 6.2.14.3. Service Benchmarking
      • 6.2.14.4. Strategic Initiatives

Chapter 7. KoL Commentary/Recommendations

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Healthcare CDMO Market, By Region 2018 - 2030 (USD Billion)
  • Table 4 Global Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 5 North America Healthcare CDMO Market, By Country, 2018 - 2030 (USD Billion)
  • Table 6 North America Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 7 U.S. Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 8 Canada Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 9 Europe Healthcare CDMO Market, By Country, 2018 - 2030 (USD Billion)
  • Table 10 Europe Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 11 UK Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 12 Germany Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 13 France Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 14 Italy Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 15 Spain Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 16 Netherlands Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 17 Belgium Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 18 Denmark Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 19 Norway Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 20 Sweden Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 21 Asia Pacific Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 22 China Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 23 Japan Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 24 India Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 25 Australia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 26 South Korea Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 27 Malaysia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 28 New Zealand Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 29 Singapore Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 30 Philippines Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 31 Thailand Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 32 Latin America Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 33 Brazil Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 34 Mexico Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 35 Argentina Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 36 Colombia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 37 Chile Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 38 Middle East & Africa Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 39 South Africa Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 40 Saudi Arabia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 41 UAE Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 42 Israel Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 43 Kuwait Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Healthcare CDMO market segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Healthcare CDMO Market Services outlook: Segment dashboard
  • Fig. 26 Healthcare CDMO: Services movement analysis
  • Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 28 Small Molecule market, 2018 - 2030 (USD Million)
  • Fig. 29 Preclinical market, 2018 - 2030 (USD Million)
  • Fig. 30 Bioanalysis and DMPK studies market, 2018 - 2030 (USD Million)
  • Fig. 31 Toxicology Testing market, 2018 - 2030 (USD Million)
  • Fig. 32 Other Preclinical Services market, 2018 - 2030 (USD Million)
  • Fig. 33 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 34 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 35 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 36 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 37 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 38 Laboratory Services market, 2018 - 2030 (USD Million)
  • Fig. 39 Bioanalytical Services market, 2018 - 2030 (USD Million)
  • Fig. 40 Analytical Services market, 2018 - 2030 (USD Million)
  • Fig. 41 Large Molecule market, 2018 - 2030 (USD Million)
  • Fig. 42 Cell Line Development market, 2018 - 2030 (USD Million)
  • Fig. 43 Process Development market, 2018 - 2030 (USD Million)
  • Fig. 44 Upstream market, 2018 - 2030 (USD Million)
  • Fig. 45 Microbial market, 2018 - 2030 (USD Million)
  • Fig. 46 Mammalian market, 2018 - 2030 (USD Million)
  • Fig. 47 Others market, 2018 - 2030 (USD Million)
  • Fig. 48 Downstream market, 2018 - 2030 (USD Million)
  • Fig. 49 MABs market, 2018 - 2030 (USD Million)
  • Fig. 50 Recombinant proteins market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Others market, 2018 - 2030 (USD Million)
  • Fig. 53 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 54 Small Molecule market, 2018 - 2030 (USD Million)
  • Fig. 55 Large Molecule market, 2018 - 2030 (USD Million)
  • Fig. 56 MABs market, 2018 - 2030 (USD Million)
  • Fig. 57 Recombinant Proteins market, 2018 - 2030 (USD Million)
  • Fig. 58 Others market, 2018 - 2030 (USD Million)
  • Fig. 59 High Potency API market, 2018 - 2030 (USD Million)
  • Fig. 60 Finished Dose Formulations market, 2018 - 2030 (USD Million)
  • Fig. 61 Solid Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 62 Liquid Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 63 Injectable Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 64 Medical Devices market, 2018 - 2030 (USD Million)
  • Fig. 65 Class I market, 2018 - 2030 (USD Million)
  • Fig. 66 Class II market, 2018 - 2030 (USD Million)
  • Fig. 67 Class III market, 2018 - 2030 (USD Million)
  • Fig. 68 Regional marketplace: Segment dashboard
  • Fig. 69 Regional outlook, 2022 & 2030
  • Fig. 70 North America market, 2018 - 2030 (USD Million)
  • Fig. 71 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 72 Canada market, 2018 - 2030 (USD Million)
  • Fig. 73 Europe market, 2018 - 2030 (USD Million)
  • Fig. 74 Germany market, 2018 - 2030 (USD Million)
  • Fig. 75 UK market, 2018 - 2030 (USD Million)
  • Fig. 76 France market, 2018 - 2030 (USD Million)
  • Fig. 77 Italy market, 2018 - 2030 (USD Million)
  • Fig. 78 Spain market, 2018 - 2030 (USD Million)
  • Fig. 79 Denmark market, 2018 - 2030(USD Million)
  • Fig. 80 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 81 Norway market, 2018 - 2030 (USD Million)
  • Fig. 82 Netherlands market, 2018 - 2030 (USD Million)
  • Fig. 83 Belgium market, 2018 - 2030 (USD Million)
  • Fig. 84 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 85 China market, 2018 - 2030 (USD Million)
  • Fig. 86 Japan market, 2018 - 2030 (USD Million)
  • Fig. 87 India market, 2018 - 2030 (USD Million)
  • Fig. 88 Australia market, 2018 - 2030 (USD Million)
  • Fig. 89 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 90 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 91 Malaysia market, 2018 - 2030 (USD Million)
  • Fig. 92 New Zealand market, 2018 - 2030 (USD Million)
  • Fig. 93 Singapore market, 2018 - 2030 (USD Million)
  • Fig. 94 Philippines market, 2018 - 2030 (USD Million)
  • Fig. 95 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 96 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 97 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 98 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 99 Colombia market, 2018 - 2030 (USD Million)
  • Fig. 100 Chile market, 2018 - 2030 (USD Million)
  • Fig. 101 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 102 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 103 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 104 UAE market, 2018 - 2030 (USD Million)
  • Fig. 105 Kuwait market, 2018 - 2030 (USD Million)
  • Fig. 106 Israel market, 2018 - 2030 (USD Million)